{"id":506548,"date":"2020-09-11T18:54:01","date_gmt":"2020-09-11T18:54:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=506548"},"modified":"2020-09-11T18:54:01","modified_gmt":"2020-09-11T18:54:01","slug":"diabetic-gastroparesis-epidemiology-forecast-till-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/diabetic-gastroparesis-epidemiology-forecast-till-2030_506548.html","title":{"rendered":"Diabetic Gastroparesis Epidemiology Forecast till 2030"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Diabetic Gastroparesis Epidemiology Forecast till 2030\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Diabetic Gastroparesis Epidemiology Forecast till 2030\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP      <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s  &#8216;Diabetic Gastroparesis Epidemiology Forecast to 2030&#8217; report delivers an in-depth understanding of the disease, historical and forecasted Diabetic Gastroparesis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/div>\n<p style=\"text-align: justify;\">Gastroparesis is a disorder affecting people with both type 1 and type 2 diabetes in which the stomach takes too long to empty its contents (delayed gastric emptying).<\/p>\n<p style=\"text-align: justify;\">Diabetic Gastroparesis (DGP) is a serious complication of diabetes that results in delayed gastric emptying with associated upper gastrointestinal symptoms in the absence of any mechanical obstruction.<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/diabetic-gastroparesis-epidemiology\" target=\"_blank\"><strong>Diabetic Gastroparesis&nbsp;Epidemiology Insights&nbsp;&nbsp;&nbsp;&nbsp; <\/strong><\/a><\/p>\n<ul style=\"text-align: justify;\">\n<li><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/diabetic-gastroparesis-epidemiology\" target=\"_blank\">The total Diabetic Gastroparesis prevalent population in the 7MM is expected to rise to <strong>17,859,995<\/strong> in 2030.&nbsp;<\/a><\/li>\n<li>About <strong>40%<\/strong> of patients with Type 1 Diabetes have Gastroparesis.<\/li>\n<li>Around <strong>30%<\/strong> of Type 2 Diabetes Mellitus (DM)&nbsp;cases suffer from Diabetic Gastroparesis.<\/li>\n<li>The prevalence of both T1DM and T2DM associated Diabetic Gastroparesis was highest in the United States.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong><span style=\"text-decoration: underline;\">Gender-specific Prevalence<\/span><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Among the Diabetic Gastroparesis patients, females account for a <strong>higher<\/strong> number in comparison to males.&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong><span style=\"text-decoration: underline;\">Symptom-associated Prevalence<\/span><\/strong><\/p>\n<p style=\"text-align: justify;\">Nausea was the most common symptom and Abdominal Pain was the least common symptom associated with Diabetic Gastroparesis.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/diabetic-gastroparesis-epidemiology\" target=\"_blank\"><strong>Request for sample pages<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Report<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>The Diabetic Gastroparesis report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns<\/li>\n<li>The Diabetic Gastroparesis Epidemiology Report and Model provide an overview of the risk factors and global trends of Diabetic Gastroparesis in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)<\/li>\n<li>The report provides insight about the historical and forecasted patient pool of Diabetic Gastroparesis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan<\/li>\n<li>The report helps to recognize the growth opportunities in the 7MM with respect to the patient population<\/li>\n<li>The report assesses the disease risk and burden and highlights the unmet needs of Diabetic Gastroparesis<\/li>\n<li>The report provides the segmentation of the Diabetic Gastroparesis epidemiology<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"> <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/diabetic-gastroparesis-epidemiology\" target=\"_blank\"><strong>Table of contents<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">1.&nbsp;Key Insights&nbsp;<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary of Diabetic Gastroparesis<\/p>\n<p style=\"text-align: justify;\">3.&nbsp;Diabetic Gastroparesis: Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">3.1.&nbsp;Introduction<\/p>\n<p style=\"text-align: justify;\">3.2.&nbsp;Sign and Symptoms<\/p>\n<p style=\"text-align: justify;\">3.3.&nbsp;Pathophysiology<\/p>\n<p style=\"text-align: justify;\">3.4.&nbsp;Risk Factors<\/p>\n<p style=\"text-align: justify;\">3.5.&nbsp;Diagnosis<\/p>\n<p style=\"text-align: justify;\">4.&nbsp;Patient Journey<\/p>\n<p style=\"text-align: justify;\">5.&nbsp;Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">5.1.&nbsp;Epidemiology Key Findings<\/p>\n<p style=\"text-align: justify;\">5.2.&nbsp;Assumptions and Rationale: 7MM<\/p>\n<p style=\"text-align: justify;\">5.3.&nbsp;Epidemiology Scenario: 7MM<\/p>\n<p style=\"text-align: justify;\">5.3.1.&nbsp;Diabetic Gastroparesis Epidemiology Scenario in the 7MM (2017- 2030)<\/p>\n<p style=\"text-align: justify;\">5.4.&nbsp;United States Epidemiology<\/p>\n<p style=\"text-align: justify;\">5.4.1.&nbsp;Diabetic Gastroparesis Epidemiology Scenario in the United States (2017- 2030)<\/p>\n<p style=\"text-align: justify;\">5.5.&nbsp;EU-5 Country-wise Epidemiology<\/p>\n<p style=\"text-align: justify;\">5.5.1. Germany Epidemiology<\/p>\n<p style=\"text-align: justify;\">5.5.1.1.&nbsp;Diabetic Gastroparesis Epidemiology Scenario in Germany (2017- 2030)<\/p>\n<p style=\"text-align: justify;\">5.5.2. France Epidemiology<\/p>\n<p style=\"text-align: justify;\">5.5.2.1.&nbsp;Diabetic Gastroparesis Epidemiology Scenario in France (2017- 2030)<\/p>\n<p style=\"text-align: justify;\">5.5.3. Italy Epidemiology<\/p>\n<p style=\"text-align: justify;\">5.5.3.1.&nbsp;Diabetic Gastroparesis Epidemiology Scenario in Italy (2017- 2030)<\/p>\n<p style=\"text-align: justify;\">5.5.4. Spain Epidemiology<\/p>\n<p style=\"text-align: justify;\">5.5.4.1.&nbsp;Diabetic Gastroparesis Epidemiology Scenario in Spain (2017- 2030)<\/p>\n<p style=\"text-align: justify;\">5.5.5. United Kingdom Epidemiology<\/p>\n<p style=\"text-align: justify;\">5.5.5.1.&nbsp;Diabetic Gastroparesis Epidemiology Scenario in the United Kingdom (2017-2030)<\/p>\n<p style=\"text-align: justify;\">5.6. Japan Epidemiology<\/p>\n<p style=\"text-align: justify;\">5.6.1.&nbsp;Diabetic Gastroparesis Epidemiology Scenario in Japan (2017- 2030)<\/p>\n<p style=\"text-align: justify;\">6.&nbsp;Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n<p style=\"text-align: justify;\">6.1.&nbsp;Diabetic Gastroparesis Treatment and Management<\/p>\n<p style=\"text-align: justify;\">6.2.&nbsp;Diabetic Gastroparesis Treatment Algorithm<\/p>\n<p style=\"text-align: justify;\">7.&nbsp;KOL Views<\/p>\n<p style=\"text-align: justify;\">8.&nbsp;Unmet Needs<\/p>\n<p style=\"text-align: justify;\">9.&nbsp;&nbsp;Appendix<\/p>\n<p style=\"text-align: justify;\">9.1.&nbsp;Bibliography<\/p>\n<p style=\"text-align: justify;\">9.2.&nbsp;Report Methodology<\/p>\n<p style=\"text-align: justify;\">10.&nbsp;DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">11.&nbsp;Disclaimer<\/p>\n<p style=\"text-align: justify;\">12.&nbsp;About DelveInsight<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56407.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Priya Maurya<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=diabetic-gastroparesis-epidemiology-forecast-till-2030\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=diabetic-gastroparesis-epidemiology-forecast-till-2030\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight&#8217;s &#8216;Diabetic Gastroparesis Epidemiology Forecast to 2030&#8217; report delivers an in-depth understanding of the disease, historical and forecasted Diabetic Gastroparesis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/diabetic-gastroparesis-epidemiology-forecast-till-2030_506548.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-506548","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/506548","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=506548"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/506548\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=506548"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=506548"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=506548"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}